Table 1.
Patient characteristics.
| Characteristics | With Hyperthermia | Without Hyperthermia |
p |
|---|---|---|---|
| n = 70 (%) | n = 51 (%) | ||
| Age (median, range) | 72 (54–80) | 71 (54–83) | 0.3381 |
| Performance status | 0.1948 | ||
| 0 | 41 (59) | 25 (49) | |
| 1 | 29 (41) | 23 (45) | |
| 2 | 0 | 2 (4) | |
| 3 | 0 | 1 (2) | |
| T stage | 0.8000 | ||
| T1 | 25 (36) | 18 (35) | |
| T2 | 31 (44) | 25 (49) | |
| T3a | 14 (20) | 8 (16) | |
| N stage | |||
| N0 | 72 (100) | 51 (100) | |
| Gleason score | 0.4774 | ||
| ≤7 | 17 (24) | 14 (28) | |
| 8 | 25 (36) | 22 (43) | |
| 9–10 | 28 (40) | 15 (29) | |
| Pretreatment PSA (ng/mL) | 0.6095 | ||
| <10 | 20 (29) | 17 (33) | |
| 10–20 | 19 (27) | 16 (31) | |
| >20 | 31 (44) | 18 (35) | |
| IMRT | |||
| 76 Gy, 38 fractions | 72 (100) | 51 (100) | |
| Total ADT duration | 0.2296 | ||
| <6 months | 2 (3) | 0 (0) | |
| 6–11 months | 46 (66) | 29 (57) | |
| ≥12 months | 22 (31) | 22 (43) | |
| Hyperthermia | |||
| Number of sessions | |||
| 1 | 1 (1) | - | |
| 2 | 1 (1) | - | |
| 3 | 3 (4) | - | |
| 4 | 2 (3) | - | |
| 5 | 49 (70) | - | |
| 6 | 12 (17) | - | |
| 7 | 2 (3) | - |
PSA, prostate-specific antigen; IMRT, intensity-modulated radiotherapy; ADT, androgen deprivation therapy.